Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.
No Thumbnail Available
Identifiers
Date
2017-05-11
Authors
Provencio, Mariano
Sabín, Pilar
Gomez-Codina, Jose
Torrente, Maria
Calvo, Virginia
Llanos, Marta
Gumá, Josep
Quero, Cristina
Blasco, Ana
Cruz, Miguel Angel
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United States and Europe. However, most of the prospective randomized studies have very little follow-up compared to the long natural history of the disease. The primary aim of this study was to investigate the long-term survival of our series of patients with follicular lymphoma. A total of 1074 patients with newly diagnosed FL were enrolled. Patients diagnosed were prospectively enrolled from 1980 to 2013. Median follow-up was 54.9 months and median overall survival is over 20 years in our series. We analyzed the patients who are still alive beyond 10 years from diagnosis in order to fully assess the prognostic factors that condition this group. Out of 166 patients who are still alive after more than 10 years of follow-up, 118 of them (73%) are free of evident clinical disease. Variables significantly associated with survival at 10 years were stage A longer follow-up and a large series demonstrated a substantial population of patients with follicular lymphoma free of disease for more than 10 years.
Description
MeSH Terms
Adult
Age Distribution
Aged
Anthracyclines
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Europe
Female
Hispanic or Latino
Humans
Kaplan-Meier Estimate
Lymphoma, Follicular
Male
Middle Aged
Prognosis
Proportional Hazards Models
Prospective Studies
Registries
Rituximab
Young Adult
Age Distribution
Aged
Anthracyclines
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Europe
Female
Hispanic or Latino
Humans
Kaplan-Meier Estimate
Lymphoma, Follicular
Male
Middle Aged
Prognosis
Proportional Hazards Models
Prospective Studies
Registries
Rituximab
Young Adult